Previous studies demonstrate that both the genetic knockdown and pharmacological inhibition of STAT5A/B partially suppresses DNA repair, thereby augmenting radiotherapy efficacy in prostate cancer cell lines [27]. The gene discussed is STAT5A; the disease is prostate cancer.